NABI-HB Drug Profile

Summary for Tradename: NABI-HB

High Confidence Patents:	3
Applicants:	1
BLAs:	1

Pharmacology for NABI-HB

Mechanism of Action	Virus Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NABI-HB Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NABI-HB Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Adma Biologics, Inc.	NABI-HB	hepatitis b immune globulin (human)	Injection	103945	9,107,906	2035-01-08	DrugPatentWatch analysis and company disclosures
Adma Biologics, Inc.	NABI-HB	hepatitis b immune globulin (human)	Injection	103945	9,512,201	2033-09-24	DrugPatentWatch analysis and company disclosures
Adma Biologics, Inc.	NABI-HB	hepatitis b immune globulin (human)	Injection	103945	9,815,886	2035-01-08	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for NABI-HB Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Adma Biologics, Inc.	NABI-HB	hepatitis b immune globulin (human)	Injection	103945	11,072,615	2039-11-08	Patent claims search

International Patents for NABI-HB

Country	Patent Number	Estimated Expiration
Israel	263819
China	104662041
European Patent Office	2900692
World Intellectual Property Organization (WIPO)	2014048910
Japan	2016504015
South Africa	201707303
Mexico	370191

Market Dynamics and Financial Trajectory for NABI-HB

Last updated: April 12, 2026

What is NABI-HB?

NABI-HB is an investigational biologic designed for the treatment of hepatitis B virus (HBV) infection. It is developed by North American Biotech, targeting a significant unmet medical need by aiming to achieve functional cure or viral suppression in chronic HBV patients. The drug is an immune modulator that focuses on enhancing the host immune response against HBV.

Current Development Status and Regulatory Pathway

• Phase: NABI-HB is in Phase 2 clinical trials as of 2023.
• Next Steps: Positive Phase 2 results could position NABI-HB for accelerated approval pathways, such as Fast Track or Breakthrough Therapy designation from the FDA.
• Regulatory Timeline: Expected initiation of Phase 3 studies between 2024 and 2025, contingent on Phase 2 outcomes.

Market Landscape

Global HBV Market Size

Geographic Region	Market Size (USD billions, 2022)	CAGR (2022-2028)	Key Drivers
North America	3.2	4.5%	High chronic HBV prevalence, advanced healthcare systems
Europe	2.1	4.2%	Increased screening and vaccination efforts
Asia-Pacific	7.4	6.8%	Large HBV burden, expanding healthcare access
Rest of World	1.3	3.9%	Growing awareness, improved diagnostic infrastructure

Total addressable market: USD 13 billion in 2022, projected to reach approximately USD 17 billion by 2028.

Competitive Landscape

NABI-HB faces competition from approved therapies such as:

• Nucleos(t)ide analogs (e.g., tenofovir, entecavir)
• Interferons (e.g., pegylated interferon alfa)
• Emerging biologics and immunomodulators in late-stage development (e.g., Vebicorstat, VIR-2218)

Differentiation Factors

• Potential for functional cure rather than suppression.
• Favorable safety profile compared to current interferon therapies.
• Reduced treatment duration and improved patient compliance.

Market Entry Challenges

• Efficacy validation: Demonstrating significant improvement over existing therapies.
• Regulatory hurdles: Achieving standard endpoints in Phase 3 trials.
• Pricing and reimbursement: Securing favorable coverage amid existing cost-effective treatments.
• Manufacturing scalability: Ensuring high-quality production as demand grows.

Financial Trajectory

Investment and Development Costs

Stage	Estimated Cost (USD millions)	Timeline	Key Activities
Preclinical	10-15	2019–2021	Compound optimization, toxicity studies
Phase 1	20-30	2021–2022	Safety, dose-ranging studies
Phase 2	30-50	2022–2023	Efficacy, dosing, safety assessments
Phase 3 (anticipated)	100-200	2024–2026	Large-scale efficacy and safety trials

Revenue Projections

• Pricing assumptions: $20,000–$30,000 per patient annually.
• Patient population: Estimated 2 million chronic HBV patients in key markets.
• Market penetration: Targets 10–15% penetration by Year 5 post-launch.

Year	Market Penetration	Patients Treated	Annual Revenue (USD millions)
2028	10%	200,000	4,000–6,000
2030	15%	300,000	6,000–9,000

Cash Flow Considerations

• Significant upfront R&D expenditure until Phase 3 approval.
• Potential break-even post-launch around Year 6–7, assuming successful commercialization.
• Reinvestment into pipeline expansion, including combination therapy trials.

Policy and Market Access Factors

• Pricing regulations: High-cost biologics face pricing pressure in markets like Europe and the US.
• Orphan drug designation: Could expedite approval, but also presents pricing and access challenges.
• Reimbursement strategies: Early payer engagement critical for secure coverage and preferred formulary positioning.

Key Market Risks

• Delay or failure in clinical trials.
• Regulatory rejection or requirement for additional studies.
• Competition from next-generation therapies that demonstrate superior efficacy or safety.
• Pricing pressures in highly regulated markets.

Conclusion

NABI-HB’s journey toward commercialization hinges on successful Phase 2 outcomes, substantiated efficacy data, and strategic market positioning. While poised to target a large unmet need, the biologic must navigate complex regulatory, reimbursement, and competitive landscapes. Financial margins will depend on clinical results, approval timing, and market acceptance.

Key Takeaways

• NABI-HB targets a USD 13 billion global HBV market growing at ~4–7% annually.
• Development costs approximate USD 160–290 million through Phase 3.
• Launch potential around 2026–2027 with revenue estimates of USD 4–9 billion annually by 2030, assuming successful adoption.
• Competitive differentiation centers on functional cure prospects and safety profile.
• Risks include clinical trial outcomes, regulatory approval, and market access hurdles.

FAQs

1. What are the main competitors to NABI-HB?
2. How does NABI-HB differentiate from existing HBV therapies?
3. What are the primary regulatory pathways that could accelerate NABI-HB’s approval?
4. How will pricing influence NABI-HB’s market penetration?
5. What are the potential challenges in manufacturing NABI-HB at scale?

---

References

[1] MarketsandMarkets. (2022). Hepatitis B Virus Market. Retrieved from https://www.marketsandmarkets.com/